Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature

Joshua Holmes · Liam G. Heaney · Lorcan P. A. McGarvey

Received: 16 December 2021 / Accepted: 9 March 2022 / Published online: 13 April 2022
© The Author(s) 2022

Abstract
Background  The extent to which objective and subjective tools has been used to measure the characteristics and burden of cough in patients with asthma has not been reported.
Objective  To review the large and extensive body of literature in asthma with the specific hypothesis that the characteristics of cough and clinical impact in this disease has only occasionally been studied.
Methods  For this systematic review, we searched EMBASE and MEDLINE databases using a combination of MeSH terms for “cough” and “asthma” for studies published up to and including end of August 2021. Studies included for analysis were confined to those undertaken in adult patients (≥ 18 years) with asthma of any severity where any tool or method to specifically measure cough was employed.
Results  Of 12,090 citations identified after our initial search, 112 full-text articles met criteria for inclusion in our analysis. We found that a broad range of objective and subjective measures have been used albeit with a lack of consistency between studies. Clinically important levels of cough associated with impaired health status were identified in patients with asthma.
Conclusion  Although cough is a common symptom in asthma, the clinical features and accompanying healthcare burden have been studied infrequently. In studies where cough was measured, the methods employed varied considerably. A more consistent use of cough-specific measurement tools is required to better determine the nature and burden of cough in asthma.

Keywords  Cough · Asthma · Objective · Subjective

Introduction

Asthma is characterised by variable expiratory airflow limitation and a range of respiratory symptoms including wheeze, chest tightness, shortness of breath and cough. In clinical practice, physicians enquire as to the severity and impact of these symptoms and the levels of treatment required to control them. This approach helps to determine disease severity for the individual patient and helps inform a treatment plan to optimise asthma control. A number of assessment tools including the Asthma Control Questionnaire (ACQ) [1] and the Asthma Quality of Life Questionnaire (AQLQ) [2] have been developed and validated for use not only in routine clinical practice but as key efficacy endpoints in clinical trials of asthma therapy. However, these tools are not without limitations including a failure to measure the impact and burden of all asthma symptoms [3].

Cough was one such symptom, not routinely captured independently of other asthma symptoms in the existing tools that measure asthma control nor typically considered as an outcome variable in therapeutic trials. This is despite evidence to suggest that cough exerts significant burden for some asthmatic patients [4]. Cough is also more prevalent in those with more poorly controlled disease [5] and can have a substantial effect on a patient’s quality of life [6].

There are a number of tools developed to specifically measure the clinical impact of cough. These include patient-reported outcome measures which gather information directly from individual patients as to cough severity and its impact on overall quality of life. In addition, there are techniques to objectively record cough frequency, i.e.

Lorcan P. A. McGarvey
l.mcgarvey@qub.ac.uk

1 Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK
2 Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, UK

* Corresponding author.
ambulatory cough monitoring, and to measure an individual patient’s cough response to inhaled tussive agents. The extent to which these objective and subjective measures of cough have been studied in patients with asthma is not known. To explore this further, a systematic review of the literature was undertaken with the specific hypothesis that despite the large and extensive body of literature in asthma, the characteristics of cough and clinical impact in this disease have only occasionally been studied.

Methods

The aim of this study is to provide a descriptive systematic review of the extent to which cough has been assessed within the asthma literature. Due to the heterogeneity of the inclusion criteria and the number of different outcome measures compared in this study, a meta-analysis was not possible. The protocol for this systematic review was submitted to Prospero (ID CRD420170587111) and details have been provided below.

Search Strategy and Selection Criteria

For inclusion of studies in this systematic review, we searched entries in both MEDLINE and EMBASE databases for studies published up to and including August 2021. The search strategy (as detailed in Table 1) used a broad range of search terms to ensure that all studies that were potentially eligible for data extraction were captured. In brief, a number of MeSH terms were used for “asthma” (as per a search strategy for asthma studies developed by the Cochrane Airways Group [7]) in conjunction with the subject heading “cough” which allowed for a large and varied yield of studies, therefore ensuring that all relevant studies would be captured.

Inclusion Criteria

(1) Studies confined to adult asthmatic patients (age > 18 years).
(2) Studies investigating asthma of any level of disease severity.
(3) Studies that use any form of tool or method to specifically measure cough in an asthmatic population. Measurement tools of interest were those designed to measure cough as a standalone clinical outcome measure. This may include but is not limited to objective cough measurements (cough frequency monitoring or cough challenge testing) and subjective measures (cough-specific quality of life questionnaires and/or patient-reported outcome measurement tools).
(4) All interventional, observational and qualitative studies were considered for data analysis providing all other criteria were met.

Exclusion Criteria

(1) Studies where cough is considered to exist primarily as a consequence of an existing co-morbidity (e.g. GORD, lung cancer, lung fibrosis).

Table 1 Search strategy

| Asthma search                                                                 | Cough search                      |
|------------------------------------------------------------------------------|-----------------------------------|
| 1. exp Asthma/                                                               | 17. exp Cough/ (Search 1)         |
| 2. asthma$.mp                                                                | 17. cough.mp (Search 2)           |
| 3. (antiasthma$ or anti-asthma$).mp                                         |                                   |
| 4. Respiratory Sounds/                                                       |                                   |
| 5. wheez$.mp                                                                 |                                   |
| 6. Bronchial Spasm/                                                         |                                   |
| 7. bronchospas$.mp                                                          |                                   |
| 8. (bronch$ adj3 spasm$).mp                                                 |                                   |
| 9. bronchoconstrict$.mp                                                     |                                   |
| 10. exp Bronchoconstriction/                                                 |                                   |
| 11. (bronch$ adj3 constrict$).mp                                            |                                   |
| 12. Bronchial Hyperreactivity/                                               |                                   |
| 13. Respiratory Hypersensitivity/                                            |                                   |
| 14. ((bronchi$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or   |                                   |
| hyperreactiv$ or allerg$ or insufficiency$)).mp                             |                                   |
| 15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp                    |                                   |
| 16. or/1-15                                                                 |                                   |

Search 1 (1949–2018): Asthma Search AND Cough (MeSH)
Search 2 (2018–August 2021): Asthma Search AND Cough (keyword)
Studies using a measurement tool not primarily designed to measure cough. For example, a questionnaire with sub-items relating to cough alongside a broader measure of respiratory symptoms or lung health status.

(3) Prevalence studies, case reports or reviews.

(4) Studies not reported in the language.

(5) Studies not conducted in humans.

**Study Selection Procedure**

An overview of the selection procedure, as per PRISMA guidelines, is detailed in Fig. 1. One reviewer (JH) initially identified and considered all titles and abstracts for potentially relevant papers. The following were removed; duplicate records, animal studies, reviews, case reports and non-English studies. In the final selection phase, two reviewers (JH and LMG) independently assessed the remaining papers. Any discordance on paper selection was resolved by discussion to achieve consensus.

**Data Analysis**

A data extraction tool based on the work of the Cochrane Collaboration was used to collect data from each study. This allowed for assessment of study characteristics, methods, participant characteristics, cough measurement tools used and outcomes/results. Due to the heterogeneity of study characteristics, a meta-analysis was not performed. Where appropriate, additional supplements were assessed during the data collection phase. Only those studies that use a specific cough measurement tool to assess cough in an asthmatic population were included for analysis.

**Risk of Bias Assessment**

Methodological quality was assessed using a series of tools depending on the design of the study being reviewed. An adapted version of the Newcastle–Ottawa Scale (NOS) for nonrandomised trials (Online Supplement) was used to assess cross-sectional studies. The NOS allows for the assessment of the risk of bias across a number of domains (selection, comparability and outcome). The selection domain assesses sampling procedures (including sample size) and the quality of asthma diagnosis which helps to determine how representative the study participants were of the asthma population. The comparability domain assesses the extent to which confounding factors have been controlled for between study groups (i.e. are comparator groups well matched). Finally, the outcome domain assesses the quality and validity of measurement tools used within each study and helps inform as to whether the conclusions reached from each study are reliable and comparable. Studies were scored as very good (studies receiving nine or ten points), good (studies receiving seven or eight points), satisfactory (studies receiving five or six points) or unsatisfactory (studies receiving zero to four points).

As the remaining studies were randomised controlled trials (RCTs), the Joanna Briggs Critical Appraisal tool for Randomised Controlled Trials [8] was used (Online Supplement). Studies were awarded points for each “yes” answer to the questions within the tool and scored as very good (studies receiving 11 to 13 points), good (studies receiving 8 to 10 points), satisfactory (studies receiving 5 to 7 points) or unsatisfactory (studies receiving 0 to 4 points).

**Results**

**Study Selection**

Of the 12,090 citations retrieved from the initial search, 11,774 studies were removed following screening based on exclusion criteria. The remaining 316 full-text articles were assessed by 2 independent reviewers and agreement reached on all with 112 studies considered eligible for data analysis.

**Diagnosis of Asthma**

There was variation in the diagnostic criteria for asthma reported in the selected studies which could be categorised as follows: reference to the use of national or international guideline-defined diagnostic criteria (n = 40); reliance on prior history of asthma and the presence of typical symptoms at time of study visit with confirmed airway hyperresponsiveness (n = 36); defined solely as ‘physician diagnosed’ (n = 22) and no record of any diagnostic criteria used (n = 14).

For cross-sectional studies, an adapted version of the NOS was used to assess quality of diagnosis (Appendix 1). Studies were awarded the highest score (2 points) if patients were diagnosed by guideline-defined criteria or following a detailed clinical assessment. Studies were also awarded 2 points if patients were established secondary care patients who were recruited following assessment of hospital records. 1 Point was awarded if patients were stated only as having “physician diagnosed” asthma or as having a known history of asthma. Finally, 0 points were awarded were patients self-reported an asthma diagnosis or were no diagnostic criteria were defined. In total, 52 (67.5%) of studies were awarded 2 points, 18 (23.4%) were awarded 1 point and 8 (10.4%) were awarded 0 points.
Disease Severity

In 58 studies, asthmatics were recruited from single category of disease severity: mild asthma (n = 26), cough-variant asthma (CVA) (n = 25) and severe asthma (n = 7). A further 32 studies assessed patients across a range of disease severities: mild to severe asthma (n = 17), mild to moderate asthma (n = 11) and moderate to severe asthma (n = 4). The remaining studies (n = 22) reported no information on disease severity or there was no mention of specific diagnostic criteria other than a statement that asthmatic patients were recruited.

Cough Measurement Tools

Many studies within this review reported findings from the use of more than one type of measurement tool. For the purpose of this review the range of tools employed have been categorised as follows: cough monitoring, cough reflex sensitivity testing, validated PRO measures and non-validated PRO measures.

When reviewing the use of cough measurement tools in RCTs compared to observational studies, there were some minor differences in the distribution of their use (Table 2). Additionally, the change in the use of cough measurement tools over time was assessed as follows: cough monitoring (1989–2020), cough challenge testing (1983–2021), validated subjective tools (1997–2020) and non-validated
subjective tools (1982–2019). The only significant finding from this analysis is the introduction of studies using specialised ambulatory cough monitoring devices only from 2016.

**Cough Monitoring**

There were 15 studies that used cough monitoring techniques to assess cough [9–23]. A full breakdown of the studies can be found within the Online Supplement.

The duration of cough recording time varied from 6 to 24 h. A range of cough frequency endpoints were reported which included total coughs, coughs per hour, cough seconds or cough events. Two additional studies monitored cough by qualitative analysis of cough sound signal [24] or by the assessment of flow dynamics and sound spectra of cough [25].

Marsden et al. reported in two studies [12, 13] that objective cough frequency was moderately correlated with subjective measures of asthma control and although cough frequency correlated closely with cough-related health status there was a poor association with subjective measures of cough severity. Higher cough frequencies were also observed in patients with asthma when compared to healthy controls [9, 16].

Two studies showed that there is an apparent diurnal variation in asthmatic cough frequency that appears to be independent of airway obstruction [9, 16]. Cough frequency was assessed in conjunction with cough challenge testing by Satia et al. [14, 15] who showed that an increased reflex sensitivity to capsaicin was associated with higher cough frequencies. These studies also showed evidence that increases in airway eosinophilia resulted in an increased sensitivity to capsaicin cough challenge and a subsequent increase in 24-h spontaneous coughing. A study from Wang et al. [17] also assessed cough frequency and cough reflex sensitivity and found that patients with severe asthma coughed considerably more during capsaicin cough challenge that those with mild/moderate asthma but did not report on the relationship between the two cough measures.

Three studies assessed the change in cough frequency following therapeutic intervention. Spector and Tan [11] showed that treatment with montelukast is effective in reducing cough frequency in patients with cough-variant asthma by 74%. Irwin et al. [10] also showed that beta-agonist therapy may not be as effective in reducing cough frequency in patients with cough-variant asthma but had an effect on reducing subjective cough severity. Finally, Faruqui et al. [23] showed that cough counts were significantly reduced in patients with severe asthma following 6 months treatment with mepolizumab.

Al-Khassaweneh and Abdelrahman [24] analysed cough sound signals and demonstrated that the “sound energy” of an asthmatic cough signal is greater than that of non-asthmatic cough, meaning that there is potential use of cough signals to potentially aid in the diagnosis of asthma. Finally, Piirila et al. [25] assessed the flow dynamics and sound spectra of cough in a number of respiratory conditions and found that peak expiratory flow is significantly lower in asthma than conditions, such as bronchitis. They also showed that, whilst the durations of the first spontaneous cough sound lasted longer than other conditions, patients with asthma subsequently had a lower number of additional spontaneous coughs.

**Measures of Cough Reflex Sensitivity**

Cough reflex sensitivity testing was undertaken in 61 studies. Methodology varied widely with a broad range of tussive agents being used. This included capsaicin (n = 37), saline (n = 7), citric acid (n = 5), histamine (n = 4), tartaric acid (n = 3), mannitol (n = 2), sodium bicarbonate (n = 1) and sodium gluconate (n = 1) (a full list and breakdown of these studies is available in the Online Supplement). In most studies, a single chemical agent was studied, but in three studies two different agents were compared. Only one study assessed physical challenge based on mechanical stimulation of the trachea using stretch, compression and vibration techniques (n = 1).

Cough reflex sensitivity was reported to be heightened in patients with asthma compared to healthy controls in eight studies [14, 26–32]. However, in contrast to this, seven studies reported no difference in reflex sensitivity between these patient groups [33–39]. There was also evidence to suggest that cough reflex sensitivity may be heightened in patients with severe or uncontrolled asthma compared to those with mild and controlled asthma [17, 37, 40].

The relationship between cough reflex sensitivity and other cough measurement tools was investigated in ten studies. Heightened cough reflex sensitivity was associated with increases in cough severity [26, 41–45], a worsening cough-related quality of life [40, 43] and an increase in cough frequency [12, 14, 15, 43]. There was also evidence to suggest

---

**Table 2** The proportion of each study type utilising different cough measurement tools either alone or in combination

| Type of Measurement Tool                        | RCTs (n = 47)* | Observational studies (n = 65)* |
|------------------------------------------------|---------------|-------------------------------|
| Cough monitoring                               | 9             | 20                            |
| Cough challenge testing                        | 47            | 60                            |
| Validated subjective measures                  | 19            | 29                            |
| Non-validated subjective measures              | 34            | 12                            |

*aTotal percentages larger than 100% as a number of studies used more than one type of cough measurement tool*
that cough reflex sensitivity is associated with measures of asthma control as measured by the Asthma Control Questionnaire (ACQ) [40] and the Asthma Control Test (ACT) [44].

There was evidence to suggest that changes in cough reflex sensitivity are not related to sputum eosinophilia [46] and levels of airway inflammation [47]. However, more recent evidence suggests that increases in airway eosinophilia may result in an increased cough reflex sensitivity to capsaicin which is also associated with increases in the amount of spontaneous coughing over 24 h [15].

Some studies provided evidence that treatment with leukotriene receptor antagonists (LTRAs) is effective at reducing cough reflex sensitivity in patients with cough-variant asthma [41, 48] but may not have the same impact in mild to moderate bronchial asthma [49]. A number of other studies also provided evidence that treatment with azelastine [50, 51], non-steroidal anti-inflammatories [52, 53], carbocysteine [54] and inhaled corticosteroid therapies [31, 36] are effective in reducing cough reflex sensitivity in mild to moderate asthma.

**Capsaicin Cough Challenge**

Although capsaicin was the most commonly implemented tussive agent within the selected studies, the cough challenge methodology varied. Differences include the number of dilutions used, the minimum and maximum concentrations used, inhalation time (single breath vs tidal breathing) and the use of placebo doses. More consistency was observed for the endpoints of the cough challenge test with most studies using the concentration required to elicit 2 ($C_2$) and/or 5 ($C_5$) coughs as the point of termination of the test.

**Validated Patient-Reported Outcome Measures**

19 Studies utilised at least one quality of life questionnaire to assess the impact of cough. The Leicester Cough Questionnaire (LCQ) ($n = 18$) was most commonly used with the Cough-Specific Quality of Life Questionnaire (CQLQ) ($n = 2$) and the Chronic Cough Impact Questionnaire ($n = 1$) used infrequently. Additionally, a number of studies employed a Visual Analogue Scale to assess cough ($n = 13$). An overview of the studies is shown in the Online Supplement.

Cough-related quality of life (QOL) was associated with asthma symptom scores [55] and measures of asthma control and asthma-related QOL [40, 56]. Additionally, there was evidence to suggest that patients with uncontrolled asthma have a worse cough-related QOL compared to patients with controlled asthma [40]. Cough QOL was also associated with markers of airway inflammation [29, 40] but showed no significant association with sputum eosinophilia [56] or blood eosinophilia [57].

There were no significant differences observed in cough-QOL between patients with idiopathic chronic cough and patients with asthma and a chronic cough [57] or those with stable asthma [6]. Additionally, patients with asthma and cough reported higher frequencies of other asthma symptoms (wheeze, dyspnoea and chest tightness) compared to those patients without chronic cough [57].

Treating asthma patients with ICS [43], tiotropium [44], procaterol [58] and azithromycin [59] all resulted in improvements in cough-related QOL. Cough severity was shown to improve following treatment with montelukast [41, 60] and beta-agonist therapy [10]. Additionally, there was evidence to suggest that providing patients with additional interactive online advice and guidelines relating to their condition can help to improve cough-related QOL [61].

**Non-validated Patient-Reported Outcome Measures for Cough**

Forty-two studies used a measurement tool which has not been validated to assess cough. A Likert scale or cough diary in conjunction with a validated cough measure was used in eighteen studies [9, 11, 26, 30, 31, 36, 42, 43, 45, 48, 50, 55, 58, 59, 62–65].

The remaining 24 studies used a measurement tool that not validated for the sole assessment of cough and consisted of Likert scales/cough diaries ($n = 19$), the European Community Respiratory Health Survey (ECRHS) ($n = 3$) and an interview ($n = 1$).

Studies that utilised a Likert scale or symptom diary were primarily used to monitor how the severity or frequency of cough changed in response to a treatment therapy. A number of studies reported reduction in cough frequency and severity scores with bronchodilator therapy [66–69]. Inhaled corticosteroid therapy was also reported to be effective either alone [70] or in combination with bronchodilators [71–73]. One study showed that increasing the dose of budesonide and formoterol therapy in the presence of cough alone significantly reduced the time to recover from symptoms compared to increasing the dose in the presence of dyspnoea or wheeze [74]. Additionally, treatment with clarithromycin [75], disodium cromoglycate [76] and LTRAs [68, 77] also showed efficacy in reducing cough symptom scores. Finally, through a questionnaire and follow-up interviews, one study [5] showed that the frequency of coughing is increased in patients with uncontrolled asthma compared to those with controlled asthma.
Discussion

The aim of this review was to determine the extent to which the characteristics and clinical consequences of cough have been specifically addressed in studies undertaken in asthmatic subjects. We hypothesised that, despite the evidence for cough as an important symptom in asthma, it has been studied infrequently. Here, we report that, of the very large number of asthma studies within the existing literature, only a relatively small number have specifically addressed cough. The studies identified employed a range of objective and subjective instruments to measure cough although we noted little consistency in the choice of tool or standardisation in its use. Our review of the eligible studies indicates that clinically important levels of cough burden exists in subgroups of asthmatic patients, which is associated with impaired health status. We also report that cough is associated with impaired asthma control that is distinct from that recorded using current asthma control questionnaires. Below we discuss our interpretation of the analysis.

Subgroups of patients with asthma show considerable levels of cough burden and morbidity. Patients with asthma cough significantly more and experience a greater impairment in health status than healthy individuals [9, 16]. Some patients with asthma also have at least as much cough-related impairment and morbidity as those with idiopathic chronic cough [6, 57].

In the current literature, most studies of cough have been confined to patients with mild disease or CVA, with only a few conducted in patients with severe asthma. In addition, direct comparisons between asthma patients of differing disease severities have been studied infrequently. However, there was evidence that patients with uncontrolled asthma have a significantly greater cough frequency [13], worse cough-related QOL [40] and heightened cough reflex sensitivity [17, 37, 40] compared to patients with milder asthma. Furthermore, cough burden was not found to be associated with increased T2 inflammation suggesting that, from a clinical management perspective, it is not clear whether an escalation in dose of inhaled or oral corticosteroids may be an effective means of symptom control for all patients. It will be important to determine whether improvement in asthma control associated with the recently approved biological therapies is accompanied by a reduction in cough burden.

Our review of the literature suggests that cough measurement tools identify factors responsible for health burden and disease control that are quite distinct to that measured using instruments, such as the Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ). These questionnaires do not specifically capture the impact of cough on disease control and their almost universal use in asthma studies over the last 30 years goes some way to explain the limited attention afforded to cough as a clinical problem.

A small proportion of studies within this review used cough monitoring to assess cough and in most cases ambulatory measurement of cough frequency was undertaken. Whilst it is apparent that an increased cough frequency is associated with poor asthma control and impaired health status there is a need to overcome technological issues including battery life and portability before it can be widely adopted in asthma clinical research.

Cough challenge testing was the most commonly used measurement tool in the studies we reviewed. However, we noted considerable heterogeneity in methodology including the choice of inhaled tussive agent or the delivery device used with little evidence of standardisation of the cough challenge protocol which hampered attempts to make comparisons between studies. It is apparent that cough reflex testing does not reliably distinguish between patients with asthma and healthy subjects calling into question its value in clinical research in asthma.

A number of the studies we analysed were therapeutic trials and used non-validated measures such as Likert scales to determine cough treatment efficacy [66, 67, 70, 75, 76, 78–80]. The use of currently available validated cough-specific patient-reported outcome measures in the design of future asthma trials should be encouraged.

As with all systematic reviews, there was variability in the quality of the studies reviewed. A number failed to provide a sample size calculation or provide information relating to predefined recruitment targets. Although there was variability in how asthma was defined or diagnosed, in the majority of selected studies reported, patients were recruited according to pre-specified national guidelines or following a systematic assessment of symptoms and physical measurements. We are reasonably confident that the findings of this review are representative of a general asthma population.

To conclude, this review has identified that, in the context of the vast asthma literature, cough has been underappreciated as a clinical problem. This is especially true in the setting of severe asthma, where disease burden is high, compounded by the effects of high dose oral steroids. There are a number of validated objective and subjective measures of cough which need to be incorporated into the design of asthma studies and clinical trials.

Author Contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by JH and LM. The first draft of the manuscript was written by JH and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding  This work was supported as part of a PhD Project funded by the Northern Ireland Department for the Economy, leveraged through RASP-UK.

Declarations

Conflict of interest  Joshua Holmes has no conflicts of interest. Liam Heaney is the Academic Lead for the UK MRC Consortium for Stratified Medicine in Severe Asthma—Industrial Pharma partners Amgen, AstraZeneca, MedImmune, Janssen, Novartis, Roche/Genentech, GlaxoSmithKline and Boehringer Ingelheim; prior project grant funding from MedImmune, Novartis UK, Roche/Genentech and GlaxoSmithKline; has taken part in Advisory Boards/Lectures supported by Chiesi, Novartis, Roche/Genentech, GlaxoSmithKline, Teva, Theravance and Vectura; has travel funding support to international respiratory meetings (AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, Teva and GlaxoSmithKline) and has taken part in asthma clinical trials (GlaxoSmithKline, Schering Plough, Synaigren, Novartis and Roche/Genentech) for which his institution was remunerated. Lorcan McGarvey reports personal fees from GSK, grants and personal fees from MERCK, personal fees from Shionogi, Bayer, Bellus Health and Nocion, grants and personal fees from Chiesi and personal fees from Applied Clinical Intelligence, outside the submitted work.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR (1999) Development and validation of a questionnaire to measure asthma control. Eur Respir J 14(4):902–907 (cited 13 March 2018)
2. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiler TK (1992) Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47:76–83 (cited 13 March 2018)
3. Wilson SR, Rand CS, Cabana MD, Fogg MB, Halterman JS, Olson L, Vollmer WM, Wright RJ, Taggart V (2012) Asthma outcomes: quality of life. J Allergy Clin Immunol 129(3 Suppl.):S88–S123
4. Osman LM, McKenzie L, Cairns J, Friend JA, Godden DJ, Legge JS, Douglas JG (2001) Patient weighting of importance of asthma symptoms. Thorax 56(2):138–142
5. Mincheva R, Ekerljung L, Bjerg A, Axelsson M, Popov TA, Lundbäck B, Löttvall J (2014) Frequent cough in unsatisfactory controlled asthma—results from the population-based West Sweden Asthma Study. Respir Res 15(1):79 (cited 9 Aug 2018)
6. Polley L, Yaman N, Heaney L, Cardwell C, Murtagh E, Ramsey J, Macmahon J, Costello RW, McGarvey L (2008) Impact of cough across different chronic respiratory diseases: comparison of two cough-specific health-related quality of life questionnaires. Chest 134(2):295–302
7. Baishnab E, Karner C (2012) Primary care based clinics for asthma. https://doi.org/10.1002/14651858.CD003533.pub2
8. Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L (2017) Chapter 3: systematic reviews of effectiveness. In: Aromataris E, Munn Z (eds) Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute, Adelaide
9. Hsu YJ, Stone RA, Logan-Sinclair RB, Worsdell M, Buist CM, Chung KF (1994) Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J 7(7):1246–1253
10. Irwin RS, French CT, Smyrnios NA, Curley FJ (1997) Interpretation of positive results of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Arch Intern Med 157(17):1981–1987
11. Spector SL, Tan RA (2004) Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol 93(3):232–236
12. Marsden PA, Smith JA, Kelsall AA, Owen E, Naylor JR, Webster D, Sumner H, Alam U, McGuinness K, Woodcock AA (2008) A comparison of objective and subjective measures of cough in asthma. J Allergy Clin Immunol 122(5):903–907 (cited 30 May 2017)
13. Marsden PA, Satia I, Ibrahim B, Woodcock A, Yates L, Donnelly I, Jolly L, Thomson NC, Fowler SJ, Smith JA (2016) Objective cough frequency, airway inflammation, and disease control in asthma. Chest 149(6):1460–1466 (cited 29 May 2017)
14. Satia I, Tsamandouras N, Holt K, Badri H, Woodhead M, Ogungbenu K, Felton TW, O’Byrne PM, Fowler SJ, Smith JA (2016) Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction. J Allergy Clin Immunol 139(3):771–779 (cited 29 May 2017)
15. Satia I, Watson R, Scime T, Dockry RJ, Sen S, Ford JW, Mitchell PD, Fowler SJ, Gauvreau GM, O’Byrne PM, Smith JA (2019) Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma. J Allergy Clin Immunol 144(3):1–9
16. Lodhi S, Smith JA, Satia I, Holt KJ, Maidstone RJ, Durrington HJ (2019) Cough rhythms in asthma: potential implication for management. J Allergy Clin Immunol Pract 5:5–8
17. Wang R, Fowler SJ, Niven R, Ryan D, Holt K, Mitchell J, Dockry R, Al-Shekily B, Satia I, Smith JA (2019) Investigating the safety of capsaicin cough challenge in severe asthma. Clin Exp Allergy 74:932–934
18. Jackson AR, Hull JJ, Hopker JG, Fletcher H, Gowers W, Birring SS, Dickinson JW (2020) The impact of a heat and moisture exchange mask on respiratory symptoms and airway response to exercise in asthma. ERJ Open Res. https://doi.org/10.1183/23120541.00271-2019
19. Rassouli F, Tinschert P, Barata F, Steurer-Stey C, Fleisch E, Puhan MA, Baty F, Kowatsch T, Brutsche MH (2020) Characteristics of asthma-related nocturnal cough: a potential new digital biomarker. J Asthma Allergy 13:649–657
20. Tinschert P, Rassouli F, Barata F, Steurer-Stey C, Fleisch E, Puhan MA, Kowatsch T, Brutsche MH (2020) Nocturnal cough and sleep quality to assess asthma control and predict attacks. J Asthma Allergy 13:669–678
21. Doenges J, Kuckuck E, Cassel W, Hildebrandt O, Weissflog A, Sohrabi K, Koehler N, Gross V, Greulich T, Koehler U (2020) Disease control in patients with asthma and respiratory symptoms (wheezing, cough) during sleep. Asthma Res Pract 6(1):9 (cited 4 March 2021)
22. Barata F, Tinschert P, Rassouli F, Steurer-Stey C, Fleisch E, Puhan MA, Brutsche M, Kotz D, Kowatsch T (2020) Automatic recognition, segmentation, and sex assignment of nocturnal asthmatic coughs and cough epochs in smartphone audio recordings: observational field study. J Med Internet Res. https://doi.org/10.2196/18082
23. Faruqi S, Sykes DL, Crooks MG, Brindle K, Thompson J, Morice AH (2020) Objective assessment of cough: an early marker of response to biological therapies in asthma? Lung 198(5):767–770
24. Al-Khassaweneh M, Abdelrahman RB (2013) A signal processing approach for the diagnosis of asthma from cough sounds. J Med Eng Technol 37(3):165–171
25. Pürüz Y, Sosnovjärvi AR (1989) Differences in acoustic and dynamic characteristics of spontaneous cough in pulmonary diseases. Chest 96(1):46–53
26. Doherty MJ, Mister R, Pearson MG, Calverley PM (2000) Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease, Thorax 55(8):643–649 (cited 1 June 2017)
27. Nakajima T, Nishimura Y, Nishiuma T, Kotani Y, Nakata H, Yokoyama M (2006) Cough sensitivity in pure cough variant asthma elicited using continuous capsaicin inhalation. Allergol Int 55:149–155 (cited 31 May 2017)
28. Fujimura M, Kamio Y, Kasahara K, Bando T, Hashimoto T, Matsumoto H, Ueda T, Nobuaki A, Ito S, Sasaki M, Miura M (2002) Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma. Eur J Clin Pharmacol 58:171–176 (cited 1 June 2017)
29. Koskela HO, Purokivi MK, Nieminen RM, Moilanen E (2012) Asthmatic cough and airway oxidative stress. Respir Physiol Neurobiol 181(3):346–350
30. Koskela HO, Purokivi MK, Kontra KM, Taivainen AH, Tukiainen HO (2008) Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clin Exp Allergy 38(7):1100–1107 (cited 31 May 2017)
31. Koskela HO, Hyvarinen L, Brannan JD, Chan H-K, Anderson SD (2004) Coughing during mannitol challenge is associated with asthma. Chest 125(6):1985–1992
32. Ohkura N, Fujimura M, Nakade Y, Okazaki A, Katayama N (2012) Heightened cough response to bronchoconstriction in cough variant asthma. Respir Physiology 176(6):964–968
33. Tatar M, Petriskova J, Zucha J, Pecova R, Hutka Z, Raffajova J, Brozmanova M (2005) Induced sputum eosinophils, bronchial reactivity, and cough sensitivity in subjects with allergic rhinitis. J Physiol Pharmacol 56(Suppl. 4):227–236
34. Millqvist E, Bende M, Löwthagden O (1998) Sensory hyperreactivity—a possible mechanism underlying cough and asthma-like symptoms. Allergy 53(12):1208–1212 (cited 1 June 2017)
35. Johansson EL, Gustafsson P, Millqvist E, Ternestén-Hasséus E (2019) Small and large airways’ reactions to inhaled capsaicin in patients with asthma, and smokers. Exp Lung Res. https://doi.org/10.1080/01902449.2019.1611971
36. Di Franco A, Dente FL, Giannini D, Vagaggini B, CONTI I, Macchioni P, Scuotri L, Taccola M, Bacci E, Paggioro PL (2001) Effects of inhaled corticosteroids on cough threshold in patients with bronchial asthma. Pulm Pharmacol Ther 14:35–40 (cited 1 June 2017)
37. Schmidt D, Jorres RA, Magnussen H (1997) Citric acid-induced cough thresholds in normal subjects, patients with bronchial asthma, and smokers. Eur J Res Med 29(4):384–388
38. Fujimura M, Sakamoto S, Kamio Y, Saito M, Miyake Y, Yasui M, Matsuda T (1992) Cough threshold to inhaled tartaric acid and bronchial responsiveness to methacholine in patients with asthma and sino-bronchial syndrome. Intern Med 31(1):17–21
39. Fujimura M, Sakamoto S, Kamio Y, Matsuda T (1992) Cough receptor sensitivity and bronchial responsiveness in normal and asthmatic subjects. Eur Respir J 5(3):291–295 (cited 2 June 2017)
40. Purokivi M, Koskela H, Kontra K (2013) Determinants of asthma control and quality of life in stable asthma: evaluation of two new cough provocation tests. Clin Respir J 7(3):253–260 (cited 30 May 2017)
41. Takemura M, Nimi A, Matsumoto H, Ueda T, Matsuo H, Yamaguchi M, Jinnai M, Chin K, Mishima M (2012) Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration 83(4):308–315 (cited 30 May 2017)
42. Shioya T, Satake M, Sano M, Kagaya M, Watanabe A, Sato K, Ito T, Nobuaki A, Ito S, Sasaki M, Miura M (2002) Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma. Eur J Clin Pharmacol 58:171–176 (cited 1 June 2017)
43. Kanemitsu Y, Matsumoto H, Oguma T, Nagasaki T, Ito I, Izuhara Y, Tajiri T, Iwata T, Mishima M, Niimi A (2019) 123 Independent factors contributing to daytime and nighttime asthmatic cough reactivity to inhaled corticosteroids. J Investig Allergol Clin Immunol 29(1):30–39
44. Fukumitsu K, Kanemitsu Y, Asano T, Takeda N, Ichikawa H, Yaj JMG, Fukuda S, Uemura T, Takakawa O, Ohkubo H, Maeno K, Ito Y, Oguri T, Nakamura A, Takemura M, Niimi A (2018) Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma. J Allergy Clin Immunol Pract 6(5):1613–1620.e2
45. Kirkpatrick MB (1986) Effect of an inhaled bronchodilator on histamine-induced cough in asthmatic subjects. Ala J Med Sci 23(2):146–150
46. Minoguchi H, Minoguchi K, Tanaka A, Matsuo H, Kihara N, Adachi M (2003) Cough receptor sensitivity to capsaicin does not change after allergen bronchoprovocation in asthmatic therapy. Thorax 58(1):19–22 (cited 31 May 2017)
47. Fujimura M, Ohkura N, Abo M, Furusho S, Waseda Y, Ichikawa Y, Har J (2008) Exhaled nitric oxide levels in patients with atopic cough and cough variant asthma. Respirology 13(3):359–364 (cited 31 May 2017)
48. Dicpinigaitis PV, Dobkin JB, Reichel J (2002) Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma 39(4):291–297
49. Dicpinigaitis PV, Dobkin JB (1999) Effect of zafirlukast on cough reflex sensitivity in asthmatics. J Asthma 36(3):265–270
50. Shioya T, Ito N, Watanabe A, Kagaya M, Sano M, Shindo T, Miura S, Kimura K, Miura M (1998) Antitussive effect of azelastine hydrochloride in patients with bronchial asthma. Arzneimittelforschung 48(2):149–153
51. Shioya T, Ito N, Sasaki M, Kagaya M, Sano M, Shindo T, Kashima M, Miura M (1996) Cough threshold for capsaicin increases by azelastine in patients with cough-variant asthma. Pulm Pharmacol 9(1):59–62
52. Ishiura Y, Fujimura M, Yamamoto H, Ishiguro T, Ohkura N, Miyu S (2009) COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. J Investig Allergol Clin Immunol 19(5):370–374 (cited 30 May 2017)
53. Fujimura M, Sakamoto S, Kamio Y, Bando T, Kurashima K, Matsuda T (1993) Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects. Thorax 48(6):615–618 (cited 2 June 2017)
54. Ishiura Y, Fujimura M, Yamamori C, Nobata K, Miyu S, Kurashima K, Michishita Y, Takegoshi T (2003) Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br J Clin Pharmacol 55(6):504–510 (cited 31 May 2017)
55. Kalpakglou AF, Kara T, Kuripek E, Kocyigit P, Ekici A, Ekici M (2005) Evaluation and impact of chronic cough: comparison of specific vs generic quality-of-life questionnaires. Ann Allergy Asthma Immunol 94(5):581–585
56. Natarajan S, Free RC, Bradding P, McGarvey L, Siddiqui S (2017) The relationship between the Leicester cough questionnaire, eosinophilic airway inflammation and asthma patient related outcomes in severe adult asthma. Respir Res 18(1):44 (cited 29 May 2017)
57. Çolak Y, Afzal S, Lange P, Laursen LC, Nordestgaard BG, Dahl M (2019) Role and impact of chronic cough in individuals with...
asthma from the general population. J Allergy Clin Immunol Pract 7(6):1783–1792 (cited 18 June 2019)
58. Bao W, Chen Q, Lin Y, Liu H, Zhao G, Chen Z, Zhou X (2013) Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma. Respiriology 18(S3):53–61 (cited 29 May 2017)
59. Hodgson D, Anderson J, Reynold C, Oborne J, Meakin G, Bailey H, Shaw D, Mortimer K, Harrison T (2016) The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial. Chest 149(4):1052–1060 (cited 29 May 2017)
60. Kawai S, Baba K, Matsubara A, Shiono H, Okada T, Yamaguchi E (2008) The efficacy of montelukast and airway mast cell profiles in patients with cough variant asthma. J Asthma 45(3):243–250
61. Cao Y, Lin S-H, Zhu D, Xu F, Chen Z-H, Shen H-H, Li W (2018) WeChat public account use improves clinical control of cough-variant asthma: a randomized controlled trial. Med Sci Monit 24:1524–1532
62. Matsumoto H, Tabuena RP, Niimi A, Inoue H, Ito I, Yamaguchi M, Otsuka K, Takeda T, Oguma T, Nakaji H, Tajiri T, Iwata T, Nagasaki T, Jinna M, Matsuoaka H, Mishima M (2012) Cough triggers and their pathophysiology in patients with prolonged or chronic cough. Allergol Int 61(1):123–132 (cited 30 May 2017)
63. Koskela HO, Purokivi MK, Romppanen J (2010) Neurotrophins in chronic cough: association with asthma but not with cough severity. Clin Respir J 4(1):45–50
64. Tanaka H, Teramoto S, Oashi K, Saikai T, Tanaka S, Suzuki K, Hashimoto M, Abe S (2001) Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 105(4):281–285
65. Lin J, Wang Z, Qiu C, Wang Z, Jiang S, Tang H, Wang X, Qiu Z, He Y, Zhao J, Shi G, Sun S, Wang L, Chen L, Wang J, Mao A (2020) A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma. J Thorac Dis 12(11):6573–6585
66. Nobata K, Fujimura M, Tsuji H, Ishiiura Y, Myou S, Nakao S, Takakura E (2006) Longitudinal changes of pulmonary function and bronchial responsiveness in cough-variant asthma treated with bronchodilators alone. Allergy Asthma Proc 27(6):479–485
67. Maiti R, Prasad CN, Jaida J, Mukkisa S, Koyagura N, Palani A (2011) Racemic salbutamol and levasalbutamol in mild persistent asthma: a comparative study of efficacy and safety. Indian J Pharmacol 43(6):638–643
68. Takaoj K, Yokohori N, Tagaya E, Kirishi S, Miyamoto T, Ochiai K, Kondo M, Nagai A (2010) Comparable effect of a leukotriene receptor antagonist and long-acting beta2-adrenergic agonist in cough variant asthma. Allergy Asthma Proc 31(5):1–2
69. Moeller M, Grimmelshauer S, Munzel U (2012) Improvement of asthma therapy by a novel formoterol multidose dry powder inhaler. Arzneimittelforschung 58(04):168–173
70. Connolly KC, Peake MD, Halpin DMG, Golightly L, Turbitt ML (2000) Challenging current asthma treatment guidelines: improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. Dis Manag Health Outcomes 7(4):217–225
71. Tagaya E, Kondo M, Kirishi S, Kawagoe M, Kubota N, Tamaoki J (2015) Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. J Asthma 52(5):512–518
72. Saluja M, Nandwani S, Tanega S (2011) Safety and efficacy of Formoterol Fumarate + Fluticasone propionate in Indian asthmatic patients. Indian J Public Health Res Dev 2(2):89–92
73. Kuna P, Kuprys-Lipińska I, Dębowski T (2015) Control of asthma in adults treated with beclomethasone and formoterol in extrafine particle formulation in a real-life setting in Poland: the CASPER noninterventional, observational trial. Pol Arch Med Wewn 125(10):731–740
74. Souma R, Sugiyama K, Masuda H, Arifuku H, Nakano K, Watanabe H, Wakayama Y, Tokita S, Tatowski M, Satoh H, Koyama K, Hayashi Y, Fukushima F, Hirata H, Arima M, Kurwasawa K, Fukuda T, Fukushima Y (2018) Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms. Asthma Res Pract 4(1):1–8
75. Gotfried MH, Jung R, Messick C, Rubinstein I, Garey KW, Rodvold KA (2004) Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res Clin Exp 65(1):1–12. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=38953428 (cited 17 June 2017)
76. Monie RD, Smith AP, Leopold D, Anderson G, Davies BH, Thomas GO (1982) 106 A double-blind clinical trial of ketotifen and disodium cromoglycate in bronchial asthma. Br J Dis Chest 76(C):383–389
77. Miwa N, Nagano T, Ohnishi H, Nishiuma T, Takenaka K, Shirotani T, Nakajima T, Dokuni R, Kawa Y, Kobayashi K, Funada Y, Kotani Y, Nishimura Y (2018) An open-label, multi-institutional, randomized study to evaluate the additive effect of a leukotriene receptor antagonist on cough score in patients with cough-variant asthma being treated with inhaled corticosteroids. Kobe J Med Sci 64(4):E134–E139
78. Miao Q, Wei PC, Fan MR, Zhang YP (2013) Clinical study on treatment of cough variant asthma by Chinese medicine. Chin J Integr Med 19(7):539–545
79. Pai H, Azvedo R, Braga A, Martins L, Sarafia-Romanhelo B, Martins M, Lin C (2015) A randomized, controlled, crossover study in patients with mild and moderate asthma undergoing treatment with traditional Chinese acupuncture. Clinics 70(10):663–669
80. RocaSerra JP, Vicaut E, Lefrancois G, Umile A (2002) Efficacy and tolerability of a new non-extrafine formulation of beclometasone HFA-134a in patients with asthma: comparison with beclometasone CFC. Clin Drug Invest 22(10):653–665

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.